Literature DB >> 3063504

Effects of diuretic drugs on the lipid profile.

R Ames1.   

Abstract

Thiazide-type diuretic drugs modify the lipoprotein profile when used in the short term treatment of hypertension. Total cholesterol increases by 6 to 7% on average because of raised concentrations of low density or very low density lipoprotein cholesterol or both. High density lipoprotein cholesterol does not change. Spironolactone has a lesser effect on lipids than do thiazides. In contrast, the methylindoline compound, indapamide, a diuretic with vasodilator activity, has produced no adverse effects on lipids or lipoproteins. Long term data on thiazide monotherapy are sparse but suggest a persistence of the lipid effect for as long as 6 years of treatment. The clinical impact of these lipid changes is unclear. Although clinical trials have proved the benefit of lowering cholesterol on the incidence of coronary heart disease, the clinical significance of these diuretic-induced increases is unknown. A clinical trial will be required to resolve the issue by comparing antihypertensive drugs with and without adverse effects on the lipid profile. Because coronary heart disease is the most common complication of mild hypertension, and as diuretic-based regimens have not succeeded in curbing it, resolution of this concern is important.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063504     DOI: 10.2165/00003495-198800362-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  27 in total

1.  beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects.

Authors:  G Berglund; O Andersson
Journal:  Lancet       Date:  1981-04-04       Impact factor: 79.321

Review 2.  The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

3.  Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial.

Authors:  G Greenberg; P J Brennan; W E Miall
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

4.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

5.  Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial.

Authors:  N L Lasser; G Grandits; A W Caggiula; J A Cutler; R H Grimm; L H Kuller; R W Sherwin; J Stamler
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

6.  Antihypertensive therapy and the risk of coronary heart disease.

Authors:  R P Ames; P Hill
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

7.  Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.

Authors:  I M Stewart
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

8.  Clinical efficacy and safety of indapamide in essential hypertension.

Authors:  J H Morledge
Journal:  Am Heart J       Date:  1983-07       Impact factor: 4.749

9.  Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents.

Authors: 
Journal:  JAMA       Date:  1982-10-22       Impact factor: 56.272

10.  Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension.

Authors:  A I Goldman; B W Steele; H W Schnaper; A E Fitz; E D Frohlich; H M Perry
Journal:  JAMA       Date:  1980-10-10       Impact factor: 56.272

View more
  4 in total

1.  Dietary sodium restriction: adverse effect on plasma lipids.

Authors:  A M Sharma; H R Arntz; A Kribben; S Schattenfroh; A Distler
Journal:  Klin Wochenschr       Date:  1990-07-05

Review 2.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Authors:  R I Ogilvie; E D Burgess; J R Cusson; R D Feldman; L A Leiter; M G Myers
Journal:  CMAJ       Date:  1993-09-01       Impact factor: 8.262

3.  Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.

Authors:  R Fogari; A Zoppi; G D Malamani; G Marasi; A Vanasia; G Villa
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

Review 4.  Hypertension and Dyslipidemia Combined Therapeutic Approaches.

Authors:  Claudio Borghi; Federica Fogacci; Davide Agnoletti; Arrigo F G Cicero
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.